Israel Active

Israel’s Prolor Biotech announced positive results in a pre-clinical trial of MOD-6030, its long-acting obesity/Type II diabetes drug. In the laboratory, the drug reduced blood glucose levels, increased insulin sensitivity, and reduced cholesterol levels compared to a placebo.

Israel’s ITGI Medical has obtained EU CE Mark for its latest stent - the AneuGraftNx. The new stent is partially covered by living tissue, greatly reducing the risk of blockages.

A team of researchers, led by Prof. Eli Sprecher of Tel Aviv Sourasky Medical Center, has discovered the genetic basis for the serious and sometimes fatal autoimmune skin disease – pemphigus vulgaris. The symptoms of the disease are blistering and sores on the skin and mucus membranes. The team worked together with Egyptian Professor Ibrahim Saleh of the University of Luebeck in Germany.

Dr. Yair Bar-Haim, of Tel Aviv University is performing his Attention Bias Modification treatment at Creighton and Nebraska Universities in Omaha. The treatment hopes to help US soldiers suffering from Post Traumatic Stress Disorder, following service in Iraq and Afghanistan.

Professor Andrew Levy of the Israel Technion describes the test that can discover which diabetics are also susceptible to heart disease. He also developed treatment using Vitamin E that has a dramatic effect on survival times for affected individuals.

20 years after his retirement, Hebrew University emeritus Professor Nathan Citri developed a novel kit enabling speedy detection of multi-drug and extremely antibiotics-resistant “superbugs”.

Researchers at Hadassah University Hospital have discovered that four genes generate an anti-aging effect on women who conceive naturally after age 45. The findings were the result of a genetic study of ultra-Orthodox Ashkenazi women from Mea She'arim who have at least six children.

Israel’s Can-Fite BioPharma has reported successful pre-clinical trials of CF101 for the treatment of anterior uveitis – the inflammation of the iris. An earlier trial found CF101 effective in treating posterior uveitis – inflammation of the retina. Uveitis is a common cause of blindness in the USA.

Ben Gurion University’s V-Smart drug delivery technology has been licensed to a New York biotechnology company. Lauren Sciences will develop the technology for treating Parkinson's, Alzheimer's, Amyotrophic Lateral Sclerosis (ALS / Lou Gehrig’s), and brain malignancies.